FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																
1. Name and Address of Reporting Person* Niihara Yutaka					2. Issuer Name and Ticker or Trading Symbol Emmaus Life Sciences, Inc. [EMMA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director _X_ 10% Owner					
(Last) (First) (Middle) 21250 HAWTHORNE BLVD., SUITE 800					3. Date of Earliest Transaction (Month/Day/Year) 09/02/2020								X Officer (give title below) Other (specify below) Chairman and CEO					
(Street)				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City	NCE, CA 9	90503 (State)	(Zip)															
		(State)	1				le I - N	lon-I)erivative	Secu	rities A			osed of, or E	Beneficia	ally Ow		
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	Execut	A. Deemed Execution Date, if ny Month/Day/Year)		Code		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)) Be Re			owing	6. Ownership Form: Direct (D) or Indirect	Benefic O) Owners	t cial ship	
						C	Code	V	Amount	or (D)	Price	•				(I) (Instr. 4))	
Common value	stock, \$0.	.001 par	09/02/2020				P		650	A	\$ 1.44 (1)	10	,679,640	579,646		D (2)		
Common stock, \$0.001 par value		09/03/2020				P		1,300	A	\$ 1.33 (3)	10	10,680,946			D (2)			
Common stock, \$0.001 par value											92	,794		I		By Ho Intern Hospi Inc. (4	ational ice,	
Common stock, \$0.001 par value											63	63,000			I	By So Niiha		
Reminder:	Report on a s	separate line	e for each class of se	ecurities l	oeneficiall	y own	ned dire	Pe	ersons w	ho re	s form	n are	not requ	ction of inf iired to res OMB cont	spond u	ınless	SEC 14	74 (9-02)
			Table I		ative Secu								y Owned					
	2. Conversion or Exercise Price of Derivative Security		tion 3A. Deem Execution any (Month/D	ed Date, if	4. 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		le ate ·)	7. Tit Amo Unde Secur	Title and mount of mount of metrlying ecurities anstr. 3 and S. Price of Derivative Security (Instr. 5) 8. Price of Derivative Deriv Security (Instr. 5) 9. Nu Derivative Deriv Security Security (Instr. 5) 9. Nu Derivative Deriv Security Security (Instr. 5) 9. Nu Derivative Deriv Security Security (Instr. 5)		Derivat Securiti Benefic Owned Followi Reporte	tive Ownership form of Derivative Security: Direct (D) or Indirect ction(s) Ownership Form of Derivative Security: Direct (D) or Indirect		11. Nature of Indirec Beneficial Ownershij (Instr. 4)				
									ate xercisable		ration	Title	Amount or Number of					

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Reporting Owner Name / Address							

Niihara Yutaka 21250 HAWTHORNE BLVD. SUITE 800 TORRANCE, CA 90503	X	X	Chairman and CEO		
--	---	---	------------------	--	--

Signatures

Yutaka Niihara, M.D., M.P.H.	09/04/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.43 to \$1.45, inclusive. The reporting person (1) undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4.
- (2) The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife.
- (3) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.29 to \$1.39, inclusive.
- (4) Hope International Hospice, Inc, is a California corporation of which Dr. Niihara and his wife are the sole shareholders and directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.